Fundraising Fox
Arrakis Therapeutics
Cambridge, US · Founded 2015 · Delaware corporation · 53 employees on LinkedIn · 9 known investors
Find your way into Arrakis Therapeutics
Sign up to see every warm intro you have to Arrakis Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Arrakis Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Arrakis Therapeutics develops RNA-targeted small-molecule (rSM) medicines, working independently and with partners to create drug candidates aimed at the root causes of disease. Its pipeline includes a candidate for Type 1 Myotonic Dystrophy (DM1), a form of muscular dystrophy.
Founders & leadership
Arrakis Therapeutics was founded in 2015 by Michael Gilman and Mark DeLong.
Board
Investors · 9
How we know: Canaan Partners's portfolio page · the company's own site · a partner's Signal profile · board seat on SEC Form D · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: the company's own site · Not right? Tell us
How we know: Advent Life Sciences's portfolio page · board seat on SEC Form D · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: HBM Healthcare Investments's portfolio page · Not right? Tell us
How we know: HBM Partners's portfolio page · Not right? Tell us
How we know: Nextech Invest's portfolio page · a partner's Signal profile · funding news · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: OUP (Osage University Partners)'s portfolio page · Not right? Tell us
How we know: Pfizer Venture Investments's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: funding news · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$28.2M disclosed across 2 rounds · 2017–2019
▶$15MraisedApr 2019 · 15 investors · BiotechnologyRule 506(b)
- Nikola TrbovicDirector
- Raj ParekhDirector
- Michael GilmanExecutive Officer, Director
- Jakob LovenDirector
- Richard GasterDirector
- Colleen CuffaroDirector
- Offering amount
- $75M
- Amount sold
- $15M
- First sale
- Apr 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$13.2MraisedMar 2017 · 8 investors · BiotechnologyRule 506(b)
- Colleen CuffaroDirector
- Michael GilmanExecutive Officer, Director
- Carolyn GreenDirector
- Alan E. WaltsDirector
- David NeafusExecutive Officer
- Raj ParekhDirector
- Russell C. PetterExecutive Officer
- Offering amount
- $41.2M
- Amount sold
- $13.2M
- First sale
- Feb 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
Companies working in the same space as Arrakis Therapeutics.
In the news
Frequently asked questions
- What does Arrakis Therapeutics do?
- Arrakis Therapeutics develops RNA-targeted small-molecule (rSM) medicines, working independently and with partners to create drug candidates aimed at the root causes of disease. Its pipeline includes a candidate for Type 1 Myotonic Dystrophy (DM1), a form of muscular dystrophy.
- Who founded Arrakis Therapeutics?
- Arrakis Therapeutics was founded by Michael Gilman, Mark DeLong in 2015.
- Who are Arrakis Therapeutics's investors?
- Arrakis Therapeutics's investors include Canaan Partners, Pfizer Ventures, Advent Life Sciences, HBM Healthcare Investments, HBM Partners, Nextech Invest, OUP (Osage University Partners), Pfizer Venture Investments and 1 more.
- How much funding has Arrakis Therapeutics raised?
- Arrakis Therapeutics has disclosed $28.2M raised across 2 rounds.
- Where is Arrakis Therapeutics headquartered?
- Arrakis Therapeutics is headquartered in Cambridge, US.